Skip to Main content Skip to Navigation
Journal articles

Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.

Abstract : Oral, but not transdermal, estrogen therapy increases the risk of venous thromboembolism (VTE) in women who are past menopause. Data from the Estrogen and Thromboembolism Risk (ESTHER) study were used to investigate the effects of the genetic polymorphism of NFE2L2 rs6721961, which may impair Nrf2-dependent hepatic conjugation of estrogen metabolites. As compared with nonusers, the odds ratio (OR) for VTE in current users of oral estrogens was 2.5 (95% confidence interval (CI): 1.3-4.8) in patients with wild-type NFE2L2 and 17.9 (95% CI: 3.7-85.7) in those with the polymorphism (interaction, P = 0.01).
Document type :
Journal articles
Complete list of metadatas

Cited literature [24 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01142843
Contributor : Pascale Sztajnbok <>
Submitted on : Thursday, April 16, 2015 - 10:08:31 AM
Last modification on : Wednesday, October 14, 2020 - 4:08:18 AM
Long-term archiving on: : Monday, September 14, 2015 - 9:36:42 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Jérôme Bouligand, Odile Cabaret, Marianne Canonico, Céline Verstuyft, Liliane Dubert, et al.. Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.. Clinical Pharmacology and Therapeutics, American Society for Clinical Pharmacology and Therapeutics, 2010, 89 (1), pp.60-4. ⟨10.1038/clpt.2010.241⟩. ⟨inserm-01142843⟩

Share

Metrics

Record views

280